📊 TCRT Key Takeaways
Is Alaunos Therapeutics, Inc. (TCRT) a Good Investment?
Alaunos Therapeutics is a clinical-stage pharmaceutical company with virtually no revenue ($5K), operating losses of $4.2M, and negative free cash flow of $3.0M—indicating a burn rate that will exhaust the $1.4M cash position in under 6 months. The company faces existential risk without immediate capital infusion or major commercial breakthrough, making it unsuitable for conservative investors.
Why Buy Alaunos Therapeutics, Inc. Stock? TCRT Key Strengths
- Zero long-term debt eliminates leverage and interest burden
- Current ratio of 2.45x provides short-term liquidity buffer
- Cash position of $1.4M offers near-term operational runway
TCRT Stock Risks: Alaunos Therapeutics, Inc. Investment Risks
- Annual cash burn of ~$2.9-3.0M against $1.4M cash reserves creates <6 month runway
- Negligible revenue ($5K) with 50% YoY decline suggests no viable product commercialization
- Negative cash flow from operations unsustainable; company faces potential insolvency without financing
- Zero insider trading activity in past 90 days indicates lack of management confidence
- As development-stage pharma, pipeline success is critical but unproven and uncertain
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Revenue growth from any pipeline advancement or product launch
- Operating cash flow trend and timing to positive operations
- Insider trading activity and management capital raises
Alaunos Therapeutics, Inc. (TCRT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.45x current ratio provides a solid financial cushion.
TCRT Profit Margin, ROE & Profitability Analysis
TCRT vs Healthcare Sector: How Alaunos Therapeutics, Inc. Compares
How Alaunos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alaunos Therapeutics, Inc. Stock Overvalued? TCRT Valuation Analysis 2026
Based on fundamental analysis, Alaunos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alaunos Therapeutics, Inc. Balance Sheet: TCRT Debt, Cash & Liquidity
TCRT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alaunos Therapeutics, Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-2.92 indicates the company is currently unprofitable.
TCRT Revenue Growth, EPS Growth & YoY Performance
TCRT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.1M | $-0.55 |
| Q2 2025 | N/A | -$1.1M | $-0.63 |
| Q1 2025 | $1.0K | -$1.1M | $-0.67 |
| Q3 2024 | N/A | -$1.1M | $-0.70 |
| Q2 2024 | $4.0K | -$1.1M | $-0.71 |
| Q1 2024 | N/A | -$1.7M | $-0.11 |
| Q3 2023 | N/A | -$8.5M | $-0.04 |
| Q2 2023 | N/A | -$8.8M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alaunos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TCRT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alaunos Therapeutics, Inc. (CIK: 0001107421)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TCRT
What is the AI rating for TCRT?
Alaunos Therapeutics, Inc. (TCRT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TCRT's key strengths?
Claude: Zero long-term debt eliminates leverage and interest burden. Current ratio of 2.45x provides short-term liquidity buffer.
What are the risks of investing in TCRT?
Claude: Annual cash burn of ~$2.9-3.0M against $1.4M cash reserves creates <6 month runway. Negligible revenue ($5K) with 50% YoY decline suggests no viable product commercialization.
What is TCRT's revenue and growth?
Alaunos Therapeutics, Inc. reported revenue of $5.0K.
Does TCRT pay dividends?
Alaunos Therapeutics, Inc. does not currently pay dividends.
Where can I find TCRT SEC filings?
Official SEC filings for Alaunos Therapeutics, Inc. (CIK: 0001107421) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TCRT's EPS?
Alaunos Therapeutics, Inc. has a diluted EPS of $-2.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TCRT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alaunos Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TCRT stock overvalued or undervalued?
Valuation metrics for TCRT: ROE of -194.0% (sector avg: 15%), net margin of -83,520.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TCRT stock in 2026?
Our dual AI analysis gives Alaunos Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TCRT's free cash flow?
Alaunos Therapeutics, Inc.'s operating cash flow is $-2.9M, with capital expenditures of $98.0K. FCF margin is -59,340.0%.
How does TCRT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -83,520.0% (avg: 12%), ROE -194.0% (avg: 15%), current ratio 2.45 (avg: 2).